PUMA BIOTECHNOLOGY, INC. Operating Lease, Impairment Loss
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Operating Lease, Impairment Loss of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseImpairmentLoss · last filed 2023-11-02
- PUMA BIOTECHNOLOGY, INC. operating lease, impairment loss for the quarter ending 2023-09-30 was $0.00.
- PUMA BIOTECHNOLOGY, INC. operating lease, impairment loss for the quarter ending 2023-06-30 was $0.00.
- PUMA BIOTECHNOLOGY, INC. operating lease, impairment loss for the quarter ending 2023-03-31 was $0.00.
- PUMA BIOTECHNOLOGY, INC. operating lease, impairment loss for fiscal 2022 was $0.00.
- PUMA BIOTECHNOLOGY, INC. operating lease, impairment loss for fiscal 2021 was $0.00.
- PUMA BIOTECHNOLOGY, INC. operating lease, impairment loss for fiscal 2020 was $0.00.
| Period end | Operating Lease, Impairment Loss 3 month | Operating Lease, Impairment Loss 6 month | Operating Lease, Impairment Loss 9 month | Operating Lease, Impairment Loss 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-03-02 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-02 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |